Article
Engineering, Environmental
Yue Zhou, Siyu Wang, Xiaoyang Liang, Zbynek Heger, Qiang Lu, Wen Li, Vojtech Adam, Nan Li
Summary: This study demonstrates that combination immune checkpoint blockade of ADAR1 and PD-1 can improve the tumor immune microenvironment and enhance immune response. By delivering shADAR1 using a nanosystem and combined treatment with an anti-PD-1 antibody, immune evasion is reduced and antitumor immunity is activated. Mechanistic and transcriptomic analysis confirm that this combination therapy regulates the abundance of immune cells.
CHEMICAL ENGINEERING JOURNAL
(2023)
Review
Cell Biology
Xiude Ren, Tao Li, Wei Zhang, Xuejun Yang
Summary: Heat-shock protein 90 (HSP90) is an important molecule chaperone associated with tumorigenesis and malignancy. It plays a role in the malignant behaviors of cancer cells, but currently there are no effective single-agent treatments. Combining HSP90 inhibitors with other anticancer therapies may be a better strategy.
Article
Immunology
Sharif Rahmy, Sanket J. J. Mishra, Sean Murphy, Brian S. J. Blagg, Xin Lu
Summary: We developed a Hsp90 beta-selective inhibitor that is cytotoxic to cancer cells without inducing heat shock response. Our findings suggest that this Hsp90 beta inhibitor can significantly enhance the efficacy of ICB therapy and has good tolerability in mice.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Engineering, Environmental
Yaru Zhang, Zhaoru Zhou, Zhimin Gao, Xinan Li, Xiaozhao Wang, Zhaocong Zheng, Jing Deng, Donglian Liu, Tieli Peng, Zhiyao Hou
Summary: In this study, CuMo-SNP nanozymes were developed for enhancing immune response through mPTT. CuMo-SNP possessed the ability to generate ROS and improve mitochondrial oxidative stress, while NO generated by GSH-responsive SNP impaired autophagy and repaired oxidative damage. Combined with immune checkpoint inhibitors, CuMo-SNP mediated mPTT intensified immune cell recruitment, increased immune response, and improved the sensitivity of tumors to ICB therapy.
CHEMICAL ENGINEERING JOURNAL
(2023)
Article
Chemistry, Multidisciplinary
Rou Xie, Yufan Wang, Fan Tong, Wenqin Yang, Ting Lei, Yufan Du, Xiaorong Wang, Zixiao Yang, Tao Gong, Maxim Shevtsov, Huile Gao
Summary: To enhance drug delivery to glioma, researchers proposed Hsp70-targeting and acid-triggered self-assembled gold nanoparticles (D-A-DA/TPP) for selective delivery of doxorubicin (DOX) to glioma. The results showed that D-A-DA/TPP can induce more glioma apoptosis and combination with PD-1 checkpoint blockade significantly improved median survival time. This study offers a potential nanocarrier combining size-tunable strategy with active targeting ability to increase drug enrichment in glioma and synergizes with PD-1 checkpoint blockade to achieve chemo-immunotherapy.
Review
Immunology
Michael Kasperkiewicz, Stefan Tukaj
Summary: This mini review briefly summarizes the promising double-edged sword of targeting Hsp90/70 in the therapy of AIBDs and COVID-19.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Yawen Wang, Haoran Yu, Mengyuan Yu, Hui Liu, Bing Zhang, Yuanyuan Wang, Simin Zhao, Qingxin Xia
Summary: The CD24 protein is expressed on the surface of various normal cells and plays a significant role in tumor development. It facilitates tumor cell proliferation, metastasis, immune evasion, and induces drug resistance. Targeting CD24 has shown significant anti-tumor effects and may represent an effective strategy for treating malignant tumors.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Jinho Kang, Hye-Jin Lee, Jimin Lee, Jinhwa Hong, Yeul Hong Kim, Mary L. Disis, Jeong-An Gim, Kyong Hwa Park
Summary: This study identified HSP90-derived MHC class II epitopes using in silico algorithms and validated their effectiveness using in vivo experiments. The HSP90 peptide vaccines showed potential for improving breast cancer treatment by activating T cells, increasing T-cell recruitment in the immune microenvironment, and rearranging TCRE3.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Stefan Tukaj, Krzysztof Sitko
Summary: Over a hundred different autoimmune diseases have been described to date, affecting various organs including the skin. The loss of immune tolerance in autoimmune diseases leads to chronic inflammation and tissue damage. Current treatments focus on immunosuppression but may cause serious adverse effects. Heat shock proteins Hsp90 and Hsp70 have been identified as potential therapeutic targets for autoimmune skin diseases.
Review
Immunology
Dia Roy, Cassandra Gilmour, Sachin Patnaik, Li Lily Wang
Summary: The dysfunctional function of tumor-specific CD8+ cytotoxic T cells is crucial in antitumor immunity, and immune checkpoint receptors (ICRs) play a major role in causing this dysfunction. Immune checkpoint inhibitors (ICIs) have become a cornerstone in cancer immunotherapy, and combinatorial immunotherapies have the potential to enhance the effectiveness of existing ICI therapies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Zeynep Eroglu, Y. Ann Chen, Inna Smalley, Jiannong Li, Joseph K. Markowitz, Andrew S. Brohl, Leticia Tetteh, Hayley Taylor, Vernon K. Sondak, Nikhil I. Khushalani, Keiran S. M. Smalley
Summary: In this study, the efficacy and safety of vemurafenib and cobimetinib in combination with different doses of the HSP90 inhibitor XL888 for the treatment of advanced melanoma were explored. The study found that this combination therapy showed activity in some patients, but also had significant toxicity.
Review
Gastroenterology & Hepatology
Byung Min Lee, Jinsil Seong
Summary: ICIs have shown clinical efficacy against most solid cancers, and recent success in combination therapy with targeted agents in hepatocellular carcinoma has accelerated the search for novel combination strategies. Additionally, radiotherapy can be combined with ICIs to modulate the tumor immune microenvironment.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Biochemistry & Molecular Biology
Tanya Ju-Ngam, Nichanun McMillan, Mamoru Yoshimizu, Hisae Kasai, Ratree Wongpanya, Prapansak Srisapoome
Summary: This research conducted molecular characterization and biofunctional analyses of Hsp40 and Hsp90 genes in giant river prawns under various stress conditions. The highest similarity scores of these genes were found with crustaceans. Expression patterns of Mr-hsp40 and Mr-hsp90 were different under Aeromonas hydrophila challenge and heat-cold shock conditions, highlighting their significant roles in stress responses.
Article
Pharmacology & Pharmacy
Lihong Li, Man Yang, Chenyao Li, Yajun Liu
Summary: HSP90 is a crucial molecular chaperone involved in cancer processes and is considered a promising target for anticancer drug development. Miltefosine and Octenidine were identified as new HSP90 inhibitors with strong and broad-spectrum anticancer activity, disrupting the chaperone function of HSP90.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2021)
Review
Oncology
Tian Tian, Zhaoming Li
Summary: Blocking therapy targeting programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) has revolutionized the treatment of malignant tumors, but patient response rates are low and drug resistance is a major concern. Combining this therapy with Tim-3 blockade may offer a promising approach to overcoming resistance in cancer immunotherapy.
FRONTIERS IN ONCOLOGY
(2021)